Compare ROP & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROP | RVMD |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | United States | United States |
| Employees | 19400 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.5B | 40.3B |
| IPO Year | 2002 | 2020 |
| Metric | ROP | RVMD |
|---|---|---|
| Price | $480.23 | $172.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 24 |
| Target Price | ★ $469.18 | $274.84 |
| AVG Volume (30 Days) | 1.1M | ★ 2.2M |
| Earning Date | 10-22-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 21.30 | N/A |
| Revenue | ★ $7,902,500,000.00 | N/A |
| Revenue This Year | $8.40 | N/A |
| Revenue Next Year | $6.29 | $223.88 |
| P/E Ratio | $22.44 | ★ N/A |
| Revenue Growth | ★ 12.26 | N/A |
| 52 Week Low | $305.96 | $67.27 |
| 52 Week High | $507.24 | $224.31 |
| Indicator | ROP | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 71.82 | 39.75 |
| Support Level | $343.75 | $137.82 |
| Resistance Level | $507.24 | $197.29 |
| Average True Range (ATR) | 12.45 | 9.84 |
| MACD | -0.12 | -1.24 |
| Stochastic Oscillator | 65.54 | 9.49 |
Roper Technologies is a holding company that reinvests cash flows from its portfolio companies into further acquisitions. The firm's operations are decentralized, while the capital allocation decisions are made at the top corporate level. As of early 2026, Roper has amassed a portfolio of nearly 30 businesses, with over three-fourths of the revenue attributable to software solutions. The firm shops for acquisitions from owner-operators, corporate carve-outs, and private equity firms, with private equity firms as the most common source for its large "platform" acquisitions.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.